In a patient with hyperthyroidism who has normal thyroid‑stimulating hormone (TSH) and free thyroxine (FT4) levels while taking methimazole 2.5 mg daily, should the methimazole dose be adjusted?

Do Not Adjust Methimazole – Continue Current Dose

Your patient is euthyroid on methimazole 2.5 mg daily with normal TSH and FT4, so you should continue the current dose without adjustment. This represents successful maintenance therapy, and the goal is to maintain this euthyroid state while monitoring for potential changes.

Rationale for Continuing Current Dose

The American Thyroid Association/American Association of Clinical Endocrinologists guidelines clearly state that methimazole should be continued for approximately 12-18 months, then tapered or discontinued if TSH is normal at that time 1. Your patient is currently in the maintenance phase with excellent biochemical control on a very low dose (2.5 mg daily), which falls within the typical maintenance range of 5-10 mg daily or lower 1.

Key Management Points:

• Normal thyroid function on low-dose methimazole indicates appropriate dosing – there is no indication to reduce or increase the dose when the patient is biochemically euthyroid
• The maintenance dose of 2.5 mg daily is already at the lower end of the therapeutic spectrum, demonstrating good disease control
• Changing the dose risks destabilizing thyroid function, potentially causing either recurrent hyperthyroidism (if reduced) or iatrogenic hypothyroidism (if increased)

Monitoring Strategy

Continue monitoring thyroid function at appropriate intervals 2:

• Every 2 months minimum during stable maintenance therapy with adapted dosing
• Check TSH and FT4 (TSH may remain suppressed for 1+ month after achieving euthyroid status, so interpret cautiously) 1, 2
• Consider adding FT3 if there are clinical concerns, as recurrence may present with predominant FT3 elevation 2

Important Caveat:

While TSH is now normal, remember that TSH normalization lags behind FT4 normalization and may remain suppressed for over a month after thyroid hormones normalize 1, 2. The combination of normal TSH AND normal FT4 confirms true euthyroid status.

Duration of Therapy Considerations

Since your patient is euthyroid on maintenance therapy, you should be planning ahead:

After 12-18 months total treatment duration 1:

• Consider measuring TRAb (TSH receptor antibodies) prior to stopping therapy – normal levels indicate greater chance of remission 1
• If TRAb is negative/normal, you can taper or discontinue methimazole
• If TRAb remains elevated, consider either:
  • Long-term low-dose methimazole (2.5-5 mg daily) for patients who prefer this approach 1
  • Definitive therapy with radioactive iodine or thyroidectomy 1

Evidence for Long-Term Low-Dose Therapy:

Recent high-quality evidence supports long-term continuation of low-dose methimazole (2.5-5 mg daily) beyond the standard 12-18 months in select patients. A 2022 randomized controlled trial demonstrated that continuing low-dose methimazole reduced recurrence rates dramatically – only 11% recurrence at 36 months versus 41.2% in those who discontinued 3. This approach is:

• Safe with no adverse effects observed during prolonged therapy 3
• Particularly beneficial for patients who refuse or cannot undergo definitive therapy
• Most appropriate when euthyroid status is stably maintained on ≤5 mg daily 2

Common Pitfalls to Avoid

1. Do not reduce the dose simply because TSH is normal – this is the therapeutic goal, not an indication for dose reduction
2. Avoid iatrogenic hypothyroidism – especially important if the patient has Graves' orbitopathy, as hypothyroidism can worsen eye disease 2
3. Do not stop monitoring – even on stable low-dose therapy, continue regular thyroid function testing
4. Do not assume remission – the patient is controlled on medication, not necessarily in remission

When to Adjust Dose

You would only adjust methimazole if:

• TSH rises above normal with normal/low FT4 → indicates overtreatment, reduce dose 1
• FT4/FT3 become elevated with suppressed TSH → indicates recurrent hyperthyroidism, increase dose
• Patient develops hypothyroidism (elevated TSH, low FT4) → reduce or temporarily discontinue

In summary: Your patient's current regimen is working perfectly. Continue methimazole 2.5 mg daily, monitor thyroid function every 2 months, and plan for either discontinuation or long-term low-dose therapy after completing 12-18 months of total treatment based on TRAb status and patient preference.